CASI: casipharmaceuticals.com Company Value to Net Income

CASI Pharmaceuticals Inc. - graphic logo of issuer CASI

CASI Pharmaceuticals (CASI) enjoys high credibility among physicians due to the development of breakthrough leukemia therapies. The company generates profit from exclusive oncology drug sales in China, ensuring a steady cash flow. The stock's price history demonstrates the value of the -0.10 metric. The business relies on integrating Western licenses into Chinese medicine, remaining dependent on local certification standards.

CASI - CASI Pharmaceuticals Price to Earnings Ratio over the range 07/04/2022 - 02/28/2026

Analytical breakdowns for CASI Pharmaceuticals

- share price and expert price forecast:
Price Performance Chart CASI Pharmaceuticals, Inc|CASI - Consensus Target
- market capitalization information:
Market Value CASI Pharmaceuticals, Inc.|CASI - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share CASI Pharmaceuticals|CASI - Company Book Value|Market Value to Book Value Ratio casipharmaceuticals.com|CASI - Aggregate Company Assets
- debt and solvency information:
Debt to Capital CASI Pharmaceuticals|CASI - Long-Term Debt to Equity|Current Liabilities to Capital CASI Pharmaceuticals, Inc|CASI - Company Aggregate Debts|Debt to Book Value Ratio CASI Pharmaceuticals, Inc.|CASI - Company Long-Term Debts|Company Current Liabilities CASI Pharmaceuticals|Quick Ratio casipharmaceuticals.com
- earnings and market ratios statistics:
CASI - Company Net Income|Company Profit Forecast CASI Pharmaceuticals|CASI - P/E Multiple|Market Cap to Projected Earnings CASI Pharmaceuticals, Inc|CASI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation CASI Pharmaceuticals, Inc.|CASI - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months CASI Pharmaceuticals|CASI - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months casipharmaceuticals.com|CASI - Earnings growth in current year|Earnings growth forecast for next year CASI Pharmaceuticals
Summary company analysis:casipharmaceuticals.com CASI
Original product of CASI Pharmaceuticals, Inc.

Investors utilize this ratio as a primary barometer of asset overvaluation, determining the investment payback period through the relationship between market capitalization and net income. The forward P/E dynamics of CASI Pharmaceuticals (CASI) reflect the monetization efficiency of Western onco-hematological developments within the Chinese market, where the ability to rapidly commercialize licensed drugs directly impacts the business's fundamental value.

Key competitors

TGTX: Company Value to Net Income|Price to Earnings Ratio ACLX (Arcellx, Inc.)|IRON (Disc Medicine Inc) - Company Value to Net Income|P/E Multiple SNDX (Syndax)|Kura - Price to Earnings Ratio|ADCT - Price to Earnings Ratio|FHTX: Price to Earnings Ratio|Vor Biopharma (VOR) - Price to Earnings Ratio|Market Cap to Earnings Nkarta (NKTX)|Price to Earnings Ratio Coeptis Therapeutics Inc.|Market Cap to Earnings Actinium Corp ATNM|P/E Multiple ESLA|markertherapeutics.com - Price to Earnings Multiple|P/E Multiple INAB (IN8bio)|ERNA - Price to Earnings Ratio|GT Biopharma Corp - P/E Multiple|APTO - P/E Multiple|Bio-Path Holdings (BPTH) - Price to Earnings Ratio|MEIP - Business Payback Period|VINC (Vincerx Pharma Inc.) - P/E Multiple